 |
24 Diseases |  |
3 Trials |
|
3 Trials |  |
144 News |  |
| «123» |
- | Leukine (sargramostim) / Partner Therap, Panvac-VF (falimarev/inalimarev) / Bavarian Nordic
Trial primary completion date, Surgery: Vaccine Therapy and Sargramostim in Treating Patients With Pancreas Cancer That Cannot Be Removed By Surgery (clinicaltrials.gov) - Oct 8, 2020
P1, N=18, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Sep 2020 --> Dec 2020
- | bintrafusp alfa (M7824) / EMD Serono, SX-682 / Syntrix, Panvac-VF (falimarev/inalimarev) / Bavarian Nordic
New P1/2 trial, Combination therapy, Metastases: Phase I/II Trial Investigating the Safety, Tolerability, Pharmacokinetics, Immune and Clinical Activity of SX-682 in Combination With BinTrafusp Alfa (M7824 or TGF-beta "Trap"/PD-L1) With CV301 TRICOM in Advanced Solid Tumors (STAT) (clinicaltrials.gov) - Oct 4, 2020
P1/2, N=105, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
- | Enrollment open, Metastases: Phase II Trial of Combination Immunotherapy in Subjects With Advanced Small Bowel and Colorectal Cancers (clinicaltrials.gov) - Sep 16, 2020
P2, N=80, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Sep 2020 --> Dec 2020 Not yet recruiting --> Recruiting
- | New P2 trial, Metastases: Phase II Trial of Combination Immunotherapy in Subjects With Advanced Small Bowel and Colorectal Cancers (clinicaltrials.gov) - Aug 6, 2020
P2, N=80, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
- || Panvac-VF (falimarev/inalimarev) / Bavarian Nordic
Trial completion date, Trial primary completion date, Combination therapy, Metastases: CV301 Combined With PD-1/L1 Blockade in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer (clinicaltrials.gov) - Jul 14, 2020
P2, N=68, Active, not recruiting, Sponsor: Bavarian Nordic
Not yet recruiting --> Recruiting Trial completion date: Nov 2023 --> Mar 2023 | Trial primary completion date: Dec 2021 --> Mar 2021
- | Leukine (sargramostim) / Partner Therap, Panvac-VF (falimarev/inalimarev) / Bavarian Nordic
Trial primary completion date, Surgery: Vaccine Therapy and Sargramostim in Treating Patients With Pancreas Cancer That Cannot Be Removed By Surgery (clinicaltrials.gov) - Apr 16, 2020
P1, N=18, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: Nov 2023 --> Mar 2023 | Trial primary completion date: Dec 2021 --> Mar 2021 Trial primary completion date: Apr 2020 --> Sep 2020
- || Panvac-VF (falimarev/inalimarev) / Bavarian Nordic
The subtype was triple positive. We have not looked at micrbiome as she started on trial well before we ever knew this may be important. Multiple new trials at NCI soon to open will be using the newer version of This vaccine called BN-CV301. (Twitter) - Feb 28, 2020
- || Panvac-VF (falimarev/inalimarev) / Bavarian Nordic
Trial completion, Combination therapy: A Trial of CV301 in Combination With Anti-PD-1 Therapy in Subjects With Non-Small Cell Lung Cancer (clinicaltrials.gov) - Feb 27, 2020
P1, N=24, Completed, Sponsor: Bavarian Nordic
Trial primary completion date: Apr 2020 --> Sep 2020 Active, not recruiting --> Completed
- | Panvac-VF (falimarev/inalimarev) / Bavarian Nordic, NN1213 / Novo Nordisk
Trial completion, Trial completion date, Combination therapy: Study of Bacillus Calmette-Guerin (BCG) Combined With PANVAC Versus BCG Alone in Adults With High Grade Non-Muscle Invasive Bladder Cancer Who Failed At Least 1 Course of BCG (clinicaltrials.gov) - Jan 22, 2020
P2, N=32, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial completion date: Feb 2020 --> May 2019
- || Panvac-VF (falimarev/inalimarev) / Bavarian Nordic
Enrollment closed, Combination therapy, Metastases: CV301 Combined With PD-1/L1 Blockade in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer (clinicaltrials.gov) - Oct 31, 2019
P2, N=68, Active, not recruiting, Sponsor: Bavarian Nordic
Active, not recruiting --> Completed | Trial completion date: Feb 2020 --> May 2019 Recruiting --> Active, not recruiting
- | Leukine (sargramostim) / Partner Therap, Panvac-VF (falimarev/inalimarev) / Bavarian Nordic
Trial primary completion date, Surgery: Vaccine Therapy and Sargramostim in Treating Patients With Pancreas Cancer That Cannot Be Removed By Surgery (clinicaltrials.gov) - Oct 21, 2019
P1, N=18, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Trial primary completion date: Oct 2019 --> Jan 2020
- || Panvac-VF (falimarev/inalimarev) / Bavarian Nordic
#BavarianNordic Updates on Phase 2 Study of #CV301 in #BladderCancer $BAVA https://t.co/tdlQI6OgZB (Twitter) - Oct 20, 2019
- | bintrafusp alfa (M7824) / EMD Serono, Panvac-VF (falimarev/inalimarev) / Bavarian Nordic, ProstVac (rilimogene galvacirepvec) / Bavarian Nordic
Trial completion date, Trial primary completion date: Combination Immunotherapy in Biochemically Recurrent Prostate Cancer (clinicaltrials.gov) - Oct 3, 2019
P2, N=34, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Oct 2019 --> Jan 2020 Trial completion date: Dec 2020 --> Dec 2023 | Trial primary completion date: Dec 2019 --> Dec 2023
- Panvac-VF (falimarev/inalimarev) / Bavarian Nordic, Opdivo (nivolumab) / Ono Pharma, BMS
Phase I trial of CV301 in combination with anti-PD-1 therapy in non-squamous NSCLC (Poster Area (Hall 4)) - Sep 11, 2019 - Abstract #ESMO2019ESMO_2744;
P1
Clinical trial identification: NCT02840994. Legal entity responsible for the study: Bavarian Nordic Inc.
- | Panvac-VF (falimarev/inalimarev) / Bavarian Nordic
P1 data, Journal, PD(L)-1 Biomarker, IO biomarker: A Phase 1 Dose Escalation Trial of BN-CV301, a Recombinant Poxviral Vaccine Targeting MUC1 and CEA with Costimulatory Molecules. (Pubmed Central) - Aug 27, 2019
The BN-CV301 vaccine can be safely administered to patients with advanced cancer. Further studies of the vaccine in combination with other agents are planned.See related commentary by Repáraz et al., p. 4871.
- | Panvac-VF (falimarev/inalimarev) / Bavarian Nordic
Journal: When cancer vaccines go viral. (Pubmed Central) - Aug 27, 2019
Heterologous viral prime/boost immunization with the BN-CV301 vaccine promotes activation of immune responses that provide a clinical benefit to cancer patients. This viral platform may be used to harbor different antigens and prime tumor immunity potentially useful for combinatorial strategies.
- ||||| Panvac-VF (falimarev/inalimarev) / Bavarian Nordic
Clinical: A Phase I Dose-Escalation Trial of BN-CV301, a Recombinant Poxviral Vaccine Targeting MUC1 and CEA with Costimulatory Molecules | Clinical Cancer Research https://t.co/Jgpqx56MFN (Twitter) - Aug 15, 2019
- ||| Panvac-VF (falimarev/inalimarev) / Bavarian Nordic
A Phase I Dose-Escalation Trial of BN-CV301, a Recombinant Poxviral Vaccine Targeting MUC1 and CEA with Costimulatory Molecules @DrGattiMays @ChrisHeery @NCICCR_MOS https://t.co/igwLviApdg (Twitter) - Aug 15, 2019
- | Panvac-VF (falimarev/inalimarev) / Bavarian Nordic, Opdivo (nivolumab) / BMS
Trial primary completion date, Combination therapy, Metastases: HCRN GI16-288: A Trial of Perioperative CV301 Vaccination in Combination With Nivolumab and Systemic Chemotherapy for Metastatic CRC (clinicaltrials.gov) - Jul 15, 2019
P2, N=78, Recruiting, Sponsor: Darren Carpizo, MD
This viral platform may be used to harbor different antigens and prime tumor immunity potentially useful for combinatorial strategies. Trial primary completion date: Jun 2019 --> Dec 2020
- ||||| Panvac-VF (falimarev/inalimarev) / Bavarian Nordic
Clinical, PD(L)-1 Biomarker, IO Biomarker: glad to read: "Furthermore, two patients with KRAS mutant colorectal cancer had prolonged SD when treated with an anti-PD-L1 antibody following BN-CV301." Might the NCT number be available? @gulleyj1 @ChrisHeery Down to 6 possibilities https://t.co/Gpgk5vgf56 #CRCtrials #CRCSM (Twitter) - Jul 14, 2019
- | Leukine (sargramostim) / Partner Therap, Panvac-VF (falimarev/inalimarev) / Bavarian Nordic
Trial primary completion date, Surgery: Vaccine Therapy and Sargramostim in Treating Patients With Pancreas Cancer That Cannot Be Removed By Surgery (clinicaltrials.gov) - Jul 5, 2019
P1, N=18, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Jun 2019 --> Dec 2020 Trial primary completion date: Jun 2019 --> Oct 2019
- | Leukine (sargramostim) / Partner Therap, Panvac-VF (falimarev/inalimarev) / Bavarian Nordic
Phase classification, Combination therapy, Metastases: PANVAC-V and PANVAC-F Vaccines Plus Sargramostim to Treat Advanced Cancer (clinicaltrials.gov) - Apr 20, 2019
P1/2, N=51, Completed, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Jun 2019 --> Oct 2019 Phase classification: P2 --> P1/2
- | Panvac-VF (falimarev/inalimarev) / Bavarian Nordic, NN1213 / Novo Nordisk
Trial completion date, Combination therapy: Study of Bacillus Calmette-Guerin (BCG) Combined With PANVAC Versus BCG Alone in Adults With High Grade Non-Muscle Invasive Bladder Cancer Who Failed At Least 1 Course of BCG (clinicaltrials.gov) - Feb 16, 2019
P2, N=32, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Phase classification: P2 --> P1/2 Trial completion date: Feb 2019 --> Feb 2020
- | Panvac-VF (falimarev/inalimarev) / Bavarian Nordic
Enrollment closed, Phase classification, Enrollment change, Trial primary completion date, Combination therapy: A Trial of CV301 in Combination With Anti-PD-1 Therapy in Subjects With Non-Small Cell Lung Cancer (clinicaltrials.gov) - Dec 16, 2018
P1, N=24, Active, not recruiting, Sponsor: Bavarian Nordic, Inc.
Trial completion date: Feb 2019 --> Feb 2020 Recruiting --> Active, not recruiting | Phase classification: P1/2 --> P1 | N=200 --> 24 | Trial primary completion date: Dec 2020 --> Jan 2020
- | Leukine (sargramostim) / Partner Therap, Panvac-VF (falimarev/inalimarev) / Bavarian Nordic
Trial primary completion date, Surgery: Vaccine Therapy and Sargramostim in Treating Patients With Pancreas Cancer That Cannot Be Removed By Surgery (clinicaltrials.gov) - Dec 14, 2018
P1, N=18, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting | Phase classification: P1/2 --> P1 | N=200 --> 24 | Trial primary completion date: Dec 2020 --> Jan 2020 Trial primary completion date: Dec 2018 --> Jun 2019
- | Panvac-VF (falimarev/inalimarev) / Bavarian Nordic, NN1213 / Novo Nordisk
Trial primary completion date, Combination therapy: Study of Bacillus Calmette-Guerin (BCG) Combined With PANVAC Versus BCG Alone in Adults With High Grade Non-Muscle Invasive Bladder Cancer Who Failed At Least 1 Course of BCG (clinicaltrials.gov) - Oct 18, 2018
P2, N=32, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Dec 2018 --> Jun 2019 Trial primary completion date: Feb 2019 --> Sep 2018
- | Panvac-VF (falimarev/inalimarev) / Bavarian Nordic, NN1213 / Novo Nordisk
Trial primary completion date, Combination therapy: Study of Bacillus Calmette-Guerin (BCG) Combined With PANVAC Versus BCG Alone in Adults With High Grade Non-Muscle Invasive Bladder Cancer Who Failed At Least 1 Course of BCG (clinicaltrials.gov) - Oct 17, 2018
P2, N=32, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Feb 2019 --> Sep 2018 Trial primary completion date: Sep 2018 --> Feb 2019
- ||| Panvac-VF (falimarev/inalimarev) / Bavarian Nordic
Enrollment open, Combination therapy, Metastases: CV301 Combined With PD-1/L1 Blockade in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer (clinicaltrials.gov) - Oct 15, 2018
P2, N=68, Recruiting, Sponsor: Bavarian Nordic
Trial primary completion date: Sep 2018 --> Feb 2019 Not yet recruiting --> Recruiting
- | Panvac-VF (falimarev/inalimarev) / Bavarian Nordic, Imfinzi (durvalumab) / AstraZeneca
Enrollment open, Combination therapy, Metastases: Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic Adenocarcinoma (clinicaltrials.gov) - Sep 27, 2018
P1/2, N=54, Recruiting, Sponsor: Georgetown University
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | bintrafusp alfa (M7824) / EMD Serono, Panvac-VF (falimarev/inalimarev) / Bavarian Nordic, ProstVac (rilimogene galvacirepvec) / Bavarian Nordic
Trial completion date, Trial primary completion date: Combination Immunotherapy in Biochemically Recurrent Prostate Cancer (clinicaltrials.gov) - Sep 25, 2018
P2, N=34, Recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Trial completion date: Jun 2020 --> Dec 2020 | Trial primary completion date: Jun 2019 --> Dec 2019
- |||| Panvac-VF (falimarev/inalimarev) / Bavarian Nordic
New P2 trial, Combination therapy, Metastases: CV301 Combined With PD-1/L1 Blockade in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer (clinicaltrials.gov) - Aug 13, 2018
P2, N=68, Not yet recruiting, Sponsor: Bavarian Nordic
- ||| Panvac-VF (falimarev/inalimarev) / Bavarian Nordic, Opdivo (nivolumab) / BMS
Enrollment open, Combination therapy, Metastases: HCRN GI16-288: A Trial of Perioperative CV301 Vaccination in Combination With Nivolumab and Systemic Chemotherapy for Metastatic CRC (clinicaltrials.gov) - Jul 13, 2018
P2, N=78, Recruiting, Sponsor: Darren Carpizo, MD
Trial completion date: Jun 2020 --> Dec 2020 | Trial primary completion date: Jun 2019 --> Dec 2019 Not yet recruiting --> Recruiting
- | Leukine (sargramostim) / Partner Therap, Panvac-VF (falimarev/inalimarev) / Bavarian Nordic
Trial primary completion date, Surgery: Vaccine Therapy and Sargramostim in Treating Patients With Pancreas Cancer That Cannot Be Removed By Surgery (clinicaltrials.gov) - Jun 19, 2018
P1, N=18, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Trial primary completion date: Nov 2013 --> Dec 2018
- |||| Panvac-VF (falimarev/inalimarev) / Bavarian Nordic, Opdivo (nivolumab) / BMS
New P2 trial, Combination therapy, Metastases: HCRN GI16-288: A Trial of Perioperative CV301 Vaccination in Combination With Nivolumab and Systemic Chemotherapy for Metastatic CRC (clinicaltrials.gov) - Jun 5, 2018
P2, N=78, Not yet recruiting, Sponsor: Darren Carpizo, MD
- | Leukine (sargramostim) / Partner Therap, Panvac-VF (falimarev/inalimarev) / Bavarian Nordic
Trial completion, Trial completion date, Combination therapy, Metastases: PANVAC-V and PANVAC-F Vaccines Plus Sargramostim to Treat Advanced Cancer (clinicaltrials.gov) - Jun 4, 2018
P2, N=51, Completed, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Nov 2013 --> Dec 2018 Active, not recruiting --> Completed | Trial completion date: Apr 2019 --> May 2018
- | Leukine (sargramostim) / Partner Therap, Panvac-VF (falimarev/inalimarev) / Bavarian Nordic
Trial completion date, Combination therapy, Metastases: PANVAC-V and PANVAC-F Vaccines Plus Sargramostim to Treat Advanced Cancer (clinicaltrials.gov) - Jun 2, 2018
P2, N=51, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed | Trial completion date: Apr 2019 --> May 2018 Trial completion date: Apr 2018 --> Apr 2019
- | Panvac-VF (falimarev/inalimarev) / Bavarian Nordic
Enrollment change, Combination therapy: Study of Bacillus Calmette-Guerin (BCG) Combined With PANVAC Versus BCG Alone in Adults With High Grade Non-Muscle Invasive Bladder Cancer Who Failed At Least 1 Course of BCG (clinicaltrials.gov) - Apr 5, 2018
P2, N=30, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: Apr 2018 --> Apr 2019 N=19 --> 30
- | bintrafusp alfa (M7824) / EMD Serono, Panvac-VF (falimarev/inalimarev) / Bavarian Nordic, ProstVac (rilimogene galvacirepvec) / Bavarian Nordic
Enrollment open: Combination Immunotherapy in Biochemically Recurrent Prostate Cancer (clinicaltrials.gov) - Mar 20, 2018
P2, N=34, Recruiting, Sponsor: National Cancer Institute (NCI)
N=19 --> 30 Not yet recruiting --> Recruiting
- | bintrafusp alfa (M7824) / EMD Serono, Panvac-VF (falimarev/inalimarev) / Bavarian Nordic, ProstVac (rilimogene galvacirepvec) / Bavarian Nordic
Trial initiation date: Combination Immunotherapy in Biochemically Recurrent Prostate Cancer (clinicaltrials.gov) - Mar 3, 2018
P2, N=34, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Initiation date: Mar 2018 --> Mar 2018
- | Leukine (sargramostim) / Partner Therap, Panvac-VF (falimarev/inalimarev) / Bavarian Nordic
Phase classification, Combination therapy, Metastases: PANVAC-V and PANVAC-F Vaccines Plus Sargramostim to Treat Advanced Cancer (clinicaltrials.gov) - Jan 31, 2018
P2, N=51, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Initiation date: Mar 2018 --> Mar 2018 Phase classification: P1 --> P2
- | Leukine (sargramostim) / Partner Therap, Panvac-VF (falimarev/inalimarev) / Bavarian Nordic
Trial primary completion date, Combination therapy, Metastases: PANVAC-V and PANVAC-F Vaccines Plus Sargramostim to Treat Advanced Cancer (clinicaltrials.gov) - Jan 25, 2018
P1, N=51, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Phase classification: P1 --> P2 Trial primary completion date: Jan 2019 --> Apr 2018
- | Panvac-VF (falimarev/inalimarev) / Bavarian Nordic
Trial primary completion date, Combination therapy: Study of Bacillus Calmette-Guerin (BCG) Combined With PANVAC Versus BCG Alone in Adults With High Grade Non-Muscle Invasive Bladder Cancer Who Failed At Least 1 Course of BCG (clinicaltrials.gov) - Jan 16, 2018
P2, N=19, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Jan 2019 --> Apr 2018 Trial primary completion date: Jan 2018 --> Sep 2018
- | Leukine (sargramostim) / Partner Therap, Panvac-VF (falimarev/inalimarev) / Bavarian Nordic
Trial primary completion date, Combination therapy, Metastases: PANVAC-V and PANVAC-F Vaccines Plus Sargramostim to Treat Advanced Cancer (clinicaltrials.gov) - Jan 5, 2018
P1, N=51, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Jan 2018 --> Sep 2018 Trial primary completion date: Jan 2018 --> Jan 2019
- ||||| Panvac-VF (falimarev/inalimarev) / Bavarian Nordic, Imfinzi (durvalumab) / AstraZeneca
New P1/2 trial, Combination therapy, Metastases: Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic Adenocarcinoma (clinicaltrials.gov) - Dec 18, 2017
P1/2, N=54, Not yet recruiting, Sponsor: Georgetown University
- | Panvac-VF (falimarev/inalimarev) / Bavarian Nordic, ProstVac (rilimogene galvacirepvec) / BMS
Journal: Analyses of Pre-therapy Peripheral Immunoscore and Response to Vaccine Therapy. (Pubmed Central) - Nov 30, 2017
In another trial, prostate cancer patients with metastatic bone lesions were randomly assigned to receive a bone-seeking radionuclide ± PROSTVAC vaccine...Larger randomized studies will be required to validate these findings. These studies, however, provide the rationale for the evaluation of refined immune cell subsets to help determine which patients may benefit most from immunotherapy.
- | bintrafusp alfa (M7824) / EMD Serono, Panvac-VF (falimarev/inalimarev) / Bavarian Nordic, ProstVac (rilimogene galvacirepvec) / Bavarian Nordic
New P2 trial: Combination Immunotherapy in Biochemically Recurrent Prostate Cancer (clinicaltrials.gov) - Oct 20, 2017
P2, N=34, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
- | Panvac-VF (falimarev/inalimarev) / Bavarian Nordic
Combination therapy: Study of Bacillus Calmette-Guerin (BCG) Combined With PANVAC Versus BCG Alone in Adults With High Grade Non-Muscle Invasive Bladder Cancer Who Failed At Least 1 Course of BCG (clinicaltrials.gov) - Oct 9, 2017
P2, N=19, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
These studies, however, provide the rationale for the evaluation of refined immune cell subsets to help determine which patients may benefit most from immunotherapy. Recruiting --> Active, not recruiting | N=54 --> 19
- ||| Panvac-VF (falimarev/inalimarev) / Bavarian Nordic
Combination therapy: A Trial of CV301 in Combination With Anti-PD-1 Therapy in Subjects With Non-Small Cell Lung Cancer (clinicaltrials.gov) - Sep 25, 2017
P1/2, N=200, Recruiting, Sponsor: Bavarian Nordic, Inc.
Recruiting --> Active, not recruiting | N=54 --> 19 N=160 --> 200
- Leukine (sargramostim) / Partner Therap, Panvac-VF (falimarev/inalimarev) / Bavarian Nordic
Combination therapy, Metastases: PANVAC-V and PANVAC-F Vaccines Plus Sargramostim to Treat Advanced Cancer (clinicaltrials.gov) - Jan 30, 2017
P1, N=51, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
N=160 --> 200 Trial primary completion date: Jan 2017 --> Jan 2018
- |||| Panvac-VF (falimarev/inalimarev) / Bavarian Nordic
Combination therapy: A Trial of CV301 in Combination With Anti-PD-1 Therapy in Subjects With Non-Small Cell Lung Cancer (clinicaltrials.gov) - Jan 18, 2017
P1/2, N=160, Recruiting, Sponsor: Bavarian Nordic, Inc.
Trial primary completion date: Jan 2017 --> Jan 2018 Not yet recruiting --> Recruiting